Search
Tony Keating says the company will now submit for FDA approval. Photo: Attila Csaszar

ResApp tumbles on study

Shares in medical tech firm ResApp Health have more than halved today, after the company released the preliminary results of a new US study on its technology.

Login

(existing subscribers)

The password field is case sensitive.
Request new password

Add your comment

Share Price

Closing price for the last 90 trading days
Powered by Morningstar ®

Top 10 Shareholders

Substantial shareholders as published in the annual report.
Powered by Morningstar ®

Total Shareholder Return as at 29/11/19

1 year TSR5 year TSR
53rdResApp Health141%107%
115thSchrole64%-40%
536thOBJ-22%-31%
804thDXN-71%
733 WA (and selected non WA) listed companies ranked by 1 year TSR relative to other companies with similar revenue
Powered by Morningstar ®

Share Transactions

05/10/17
$65k Bought
16/12/16
$49k Bought
16/12/16
$49k Other
Total value as at the date of the transaction
Powered by Morningstar ®

Revenue

104th↑ResApp Health$2.7m
105th↑OBJ$2.7m
107th↑Schrole$2.7m
108th-DXN$2.6m
197 listed industrial companies ranked by revenue.
Powered by Morningstar ®